Fig. 3 | Scientific Reports

Fig. 3

From: Autoantibody spark response predicts treatment outcome in patients receiving chemoradiation followed by durvalumab therapy

Fig. 3The alternative text for this image may have been generated using AI.

Relationships between the SR/HSR and clinical outcomes. (A) The heatmap illustrates the fold change in the SR/HSR of autoantibodies per patient, while the bar graph displays the PFS. The values in the tiles represent the fold change. Patients with HSR of autoantibodies had prolonged PFS. (B) Twelve autoantibody titer changes associated with SR/HSR were detected in 20 patients. SR spark response, HSR hyper-spark response, PFS progression-free survival, CRT chemoradiotherapy, CR recurrence-free group, PD non-CR group, ICI immune checkpoint inhibitor, irAE immune-related adverse events.

Back to article page